Alluvi, known as BI 4744, presents a notable breakthrough in obesity treatment. This dual stimulator targeting both GLP-1 and GIP sites demonstrates remarkable results in research assessments, potentially surpassing https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/